182009-04-7

Basic information

• Product Name: PeMetrexed EP IMpurity E
• Synonyms: PeMetrexed EP IMpurity E;(R)-2-(4-(2-(2-amino-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl)benzamido)pentanedioic acid;Pemetrexed BP Impurity E;Pemetrexed Impurity 10
• CAS NO: 182009-04-7
• Molecular Formula: C₂₀H₂₁N₅O₆
• Molecular Weight: 427.41064
• Mol File: 182009-04-7.mol
• Article Data: 0

Chemical Properties

• Appearance: /
• Density: 1.59±0.1 g/cm3(Predicted)
• PKA: 3.58±0.10(Predicted)
• CAS DataBase Reference: PeMetrexed EP IMpurity E(CAS DataBase Reference)
• NIST Chemistry Reference: PeMetrexed EP IMpurity E(182009-04-7)
• EPA Substance Registry System: PeMetrexed EP IMpurity E(182009-04-7)

Safety Data

• Hazardous Substances Data: 182009-04-7(Hazardous Substances Data)

Usage

Description

PeMetrexed EP IMpurity E, also known as (R)-Pemetrexed, is a compound related to Pemetrexed (A604980). It is a pharmaceutical impurity derived from the parent compound Pemetrexed, which is a chemotherapy drug used in the treatment of various types of cancer.

Uses

Used in Pharmaceutical Industry:
PeMetrexed EP IMpurity E is used as a pharmaceutical impurity for the development and manufacturing of Pemetrexed, a chemotherapy drug. It plays a crucial role in ensuring the quality, safety, and efficacy of the final drug product by adhering to the regulatory standards set by the European Pharmacopeia (EP).
Used in Anticancer Applications:
PeMetrexed EP IMpurity E is related to Pemetrexed, which is employed as an anticancer agent, particularly in the treatment of malignant pleural mesothelioma (MPM). It works by inhibiting multiple folate-dependent enzymes, thus disrupting the synthesis of nucleotides and DNA, leading to the prevention of cancer cell growth and proliferation.

Downstream Products

• 193281-00-4 2-{4-[2-(2-amino-4,6-dioxo-4,5,6,7-tetrahydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)-ethyl]-benzoylamino}-pentanedioic acid